Placebo News and Research

RSS

FDA updates Zelnorm labeling a treatment of women with irritable bowel syndrome

The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.

30 Apr 2004

Cinacalcet drug more successful than a placebo in treating hyperparathyroidism

Research led by Saint Louis University physicians has shown that a new drug can help control one of the most common side effects of kidney disease.

29 Apr 2004

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Two studies presented today at the American Academy of Neurology (AAN) 56th Annual Meeting show that pregabalin, when used as an add-on treatment for epilepsy, does not affect male reproductive function or interfere with the effectiveness of oral contraceptives.

29 Apr 2004

Study of an oral fumarate shows improvement in psoriasis

Biogen Idec and Fumapharm AG today announced results from a Phase II study of BG-12, an oral fumarate, in patients with severe psoriasis.

29 Apr 2004

A popular supplement, coenzyme Q10 (CoQ10), may help prevent migraine

Migraine patients who took 100 mg three times a day of CoQ10—which acts as the body’s energy producer—had fewer attacks in three months than those who took a placebo. The participants taking CoQ10 also had fewer days with a headache and fewer days with nausea.

28 Apr 2004

Results look promising in Alzheimer’s gene therapy trial

Surgical placement of genetically modified tissue directly into the brains of patients with Alzheimer’s disease, an experimental approach to delaying brain cell loss associated with the disease, leads to increased metabolic activity in the brain, with cells apparently responding to the insertion of growth factor-producing grafts

28 Apr 2004

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Results from a large-scale, randomized, double-blind study show MIRAPEX(R) (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS).

28 Apr 2004

$Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year$

Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year

Results of a new analysis found that, without treatment, one out of 13 postmenopausal osteoporotic women who were initially fracture-free were likely to experience a spinal fracture within one year.

28 Apr 2004

Serono says Rebif an effective treatment for brain lesions

New long-term data support the importance of early treatment with high dose, high frequency Rebif® (interferon beta-1a) 44 mcg in reducing the long-term accumulation of brain lesion volume in patients with relapsing remitting multiple sclerosis (MS).

28 Apr 2004

New standard may minimize the risks and exaggerated benefits of medications

Pharmaceutical ads marketed directly to the consumer may minimize the risks and exaggerate the benefits of medications, often confusing the public about what drugs are most effective, but Dartmouth Medical School (DMS) researchers have found a remedy.

28 Apr 2004

Blood pressure drug helps delay ischemic brain damage in stroke patients

A drug used to lower blood pressure can help stop or delay the progress of further ischemic brain lesions in stroke patients according to research that will be presented at the American Academy of Neurology 56th Annual Meeting in San Francisco, Calif., April 24 – May 1, 2004.

27 Apr 2004

Antiepileptic drug levetiracetam (Keppra) shown to help chronic daily headaches

The antiepileptic drug levetiracetam (Keppra(R)) significantly reduced the frequency and impact of headaches in patients diagnosed with transformed migraine, according to a new study presented today at the 56th annual meeting of the American Academy of Neurology (AAN).

27 Apr 2004

Inspire announces positive results in cystic fibrosis study

Inspire Pharmaceuticals, Inc. today announced top-line results in a Phase II study of INS37217 Respiratory in patients with mild cystic fibrosis (CF) lung disease.

27 Apr 2004

Parkinson’s disease drug Pergolide effective in treating restless legs syndrome

Pergolide, a drug commonly used to treat Parkinson’s disease symptoms, has recently been shown to be effective in treating restless legs syndrome. Researchers from seven countries collaborated on the study, published in the April 27 issue of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2004

Alzheimer’s drug has been shown to improve memory and cognition in multiple sclerosis (MS) patients

A drug widely used for treating dementia in Alzheimer’s patients has been shown to improve memory and cognition in multiple sclerosis (MS) patients who are mild to moderately cognitively impaired.

26 Apr 2004

New cancer drug Tarceva - a breakthrough with significant survival benefit in patients with advanced lung cancer

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.

26 Apr 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

SSRI antidepressants may be unsuitable for children

A UK study in this week's issue of THE LANCET suggests that reliance on published studies alone to guide the treatment of childhood depression could be inappropriate. A systematic review including published and unpublished data shows that only one drug, fluoxetine (Prozac), was not associated with negative outcomes for children with depression.

22 Apr 2004

Breast cancer reduction findings need further investigation

Last month, an observational study conducted by the Women’s Health Initiative (WHI) was halted prematurely because of possible risks associated with the use of conjugated equine estrogen (CEE) therapy in women who have undergone hysterectomy.

22 Apr 2004

FDA Approves PROSCAR® Combined With Doxazosin to Reduce the Risk of Benign Prostatic Hyperplasia Symptoms

Merck & Co., Inc. today announced that the Food and Drug Administration (FDA) has approved changes to the prescribing information for PROSCAR® (finasteride) based on a landmark National Institutes of Health (NIH) study.

20 Apr 2004